Secukinumab improves patient perception of anxiety and depression in patients with moderate to severe psoriasis. A post hoc analysis of the SUPREME study

This study evaluated whether secukinumab treatment for patients with moderate to severe plaque psoriasis correlates with improvements in symptoms of anxiety and depression. SUPREME was a 24-week, phase IIIb, multicentre, prospective study conducted across 50 centres in Italy with an extension period of up to 72 weeks. Assessments used were: Psoriasis Area Severity Index (PASI), Hospital Anxiety and Depression Scale (HADS) – Anxiety (HADS-A), and HADS – Depression (HADS-D) scores and Dermatology Quality Life Index (DLQI). Compared with baseline, a significantly greater proportion of patients who reported moderate to severe clinical symptoms of anxiety or depression (HADSA or HADS-D ≥11) were free of moderate to severe symptoms at weeks 16 and 48. The PASI and DLQI scores reduced over time with secukinumab treatment. Psoriasis treatment with secukinumab for 48 weeks resulted in significantly improved skin clearance and a parallel improvement in symptoms of anxiety and depression, assessed by HADS

Point of view - why hypertension is overdiagnosed and overtreated in 1987

1. The decision whether arterial blood pressure (BP) is elevated or normal is usually based on inadequate data: few readings in the presence of great variability of BP; levels higher in the presence of the doctor; and diastolic BP often higher sitting and standing than lying. 2. Assessments of response and of the need for increases in drug dosage are also based on insufficient data. 3. Increased morbidity and mortality from stroke and heart attack, and incomplete correction with treatment have been interpreted as suggesting further benefit from aggressive reduction of BP to ‘normal’ in all patients. 4. The emergence of powerful drugs with few side‐effects, and the promise of lowering office BP to ‘normal’ as monotherapy, has removed the hesitation to treat ‘mild’ hypertension. 5. Attempts to lower sitting office diastolic BP to ‘normal’ have led to increasing drug dosage, dose‐related, drug‐specific side‐effects, and lethargy due to hypotension. 6. Newer self‐measurement BP units can be used easily by most patients, cost less than five visits to the doctor and provide a cheap method of obtaining sufficient data on which to base informed management decisions. Supported by normal echocardio‐graphic left ventricular mass, normal ‘home BP’ (including lying diastolic) permits many mild hypertensives to remain off medications. 7. Non‐drug therapy avoids or reduces long‐term drug therapy, with its side‐effects